To describe the clinical effects of a novel, combined ocular lubricant for treating patients with dry eye disease. A noncomparative, retrospective cohort of 67 eyes (67 patients) with a confirmed diagnosis of dry eye disease using the ocular surface disease index (>12), tear osmolarity, and ocular surface parameters (noninvasive break-up time, meniscus height, and meibography) evaluated using the Cornea550 were included. All patients were treated with a combination of 0.5% carboxymethylcellulose, glycerin 0.9%, and trehalose 3% with a dosing regimen of one drop four times a day for 1 month with a final evaluation of the same parameters. We included 67 eyes (80.6% females) with a mean age of 48.3 ± 16.2 years (standard deviation [SD]). In total, 37% of the subjects had comorbidities such as hypothyroidism (9%), ocular rosacea (4%), Sjogren's syndrome (4%), and arterial hypertension (4%). Of these, 34% were taking systemic medications and 56.7% had previous ocular surgery. The mean ocular surface disease index score before treatment was 57.6 ± 17.2 (SD) and 22.2 ± 12.9 points (SD) after treatment ( < 0.05). Other parameters such as noninvasive break-up time, meniscus height, and meibography improved without a statistically significant difference. Cristal Tears Plus is a novel, combined, and multipurpose treatment for dry eye disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/jop.2024.0115 | DOI Listing |
Med Hypothesis Discov Innov Ophthalmol
February 2025
School of Graduate Studies (SGS), Management & Science University (MSU), Shah Alam, Selangor, Malaysia.
Background: The Ocular Surface Disease Index (OSDI) questionnaire was first introduced and developed in 1997 by the Outcomes Research Group, and was adopted by Allergan, Inc. (Irvine, Goleta, CA). While several tools are available for evaluating dry eye syndrome (DES), the OSDI questionnaire is known to have high reliability and validity.
View Article and Find Full Text PDFBMC Ophthalmol
March 2025
Department of Ophthalmology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK.
Background: Faricimab is a novel anti-vascular endothelial growth factor agent, used to treat patients with neovascular age-related macular degeneration (nAMD). This study assessed efficacy and safety of faricimab in previously treated eyes.
Methods: This retrospective study included previously treated nAMD patients who had received at least three faricimab injections.
Sci Rep
March 2025
Department of Ophthalmology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan.
Eye washing is a common over-the-counter, self-administered method for managing hay fever-related ocular symptoms. However, epidemiological data on eyewash users with hay fever and their characteristics are limited. This study aimed to profile eyewash usage and preferences in individuals with hay fever.
View Article and Find Full Text PDFExp Eye Res
March 2025
Department of Ophthalmology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing, China. Electronic address:
Dry eye disease (DED) is a complex ocular condition characterized by oxidative stress, inflammation, and apoptosis. An increasing number of studies suggest that Sirtuin3 (SIRT3), a mitochondrial deacetylase, may offer protection against related pathologies. Despite these indications, the precise function and underlying mechanisms of SIRT3 in the context of DED have not been fully elucidated.
View Article and Find Full Text PDFJ Ophthalmic Inflamm Infect
March 2025
Aier Eye Hospital of Wuhan University (Hankou Aier), WuHan, HuBei, 430000, China.
Thyroid associated eye disease combined with dry eyes is a common clinical disease and has gradually received clinical attention. Its onset is caused by various factors such as eyelid dynamic change and immune inflammation, involving tear secretion, tear discharge, tear quality and other aspects. This article systematically reviews the research related to its immune factors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!